ARBUTUS BIOPHARMA CORP (ABUS)
Health Care · biotechnology · NASDAQ
A clinical-stage biopharmaceutical company developing novel treatments for chronic hepatitis B while generating value from its lipid nanoparticle drug delivery patent portfolio.
What ARBUTUS BIOPHARMA CORP does
Arbutus Biopharma Corporation is a biopharmaceutical company focused on the development of therapies for chronic hepatitis B virus (HBV) infection. The company also manages a portfolio of intellectual property related to lipid nanoparticle (LNP) delivery technology, which is the subject of ongoing patent infringement litigation and licensing agreements.
Themes: chronic hepatitis B, biotechnology, drug delivery technology, patent litigation
Fundamentals
- Price$4.33 as of 2026-10-20 close
- Market cap$857M as of 2026-08-10 (share count; price 2026-10-20)
- 1-year return-4.8% 2025-10-20 close $4.55 → 2026-10-20 close $4.33
- P/E5.48 as of 2026-10-20
- Net margin-237.9% FY2025, SEC XBRL
- ROE-43.7% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.00 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+128.2% FY2025, SEC XBRL
- Revenue CAGR (3y)-28.8% SEC XBRL
- Beta0.95 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ABUS compares in its sector
- price-to-earnings ratiobottom 10% 181 covered Health Care peers, as of 2026-10-20
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $1M | -$6M | -$5M | -$0.03 | -$6M† | — |
| Q1 FY2026 2026-03-31 | $179M | $169M | $170M | $0.87 | -$8M | — |
| Q4 FY2025 2025-12-31 | $1M† | -$5M† | -$4M† | -$0.01† | -$5M† | $0† |
| Q3 FY2025 2025-09-30 | $529000 | -$9M | -$8M | -$0.04 | -$6M† | $0† |
| Q2 FY2025 2025-06-30 | $11M | $1M | $3M | $0.01 | -$16M† | $0† |
| Q1 FY2025 2025-03-31 | $2M | -$26M | -$25M | -$0.13 | -$13M | $0 |
| Q4 FY2024 2024-12-31 | $2M† | -$14M† | -$13M† | -$0.07† | -$10M† | $86000† |
| Q3 FY2024 2024-09-30 | $1M | -$21M | -$20M | -$0.10 | -$21M† | $0† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$19M
- Short-term investments$73M
- Total debt$0 borrowings only; leases excluded
- Net debt-$93M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How ARBUTUS BIOPHARMA CORP looks technically
ARBUTUS BIOPHARMA CORP (ABUS) is trading 4.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 74 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago. It is 20.5% below its highest point of the past year. Trading volume is unusually light — only about 31% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 4.3% below its 200-day average, the long-term trend line — a long-term downtrend | -4.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.79 | $4.79 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.52 | $4.52 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 50 calendar days ago — the swings before that are what the structure reading is measured on | 50 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 74 trading days ago — a "golden cross", a bullish long-term signal | 74 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 32.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 41.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($4.05 to $4.80) — its "stochastic" reading is 37 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 37.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.45 | $5.45 |
|---|---|---|
| From the 52-week high | it is 20.5% below its 52-week high (its highest price of the past year) | -20.5% |
| Above the 52-week low | it is 23.7% above its 52-week low (its lowest price of the past year) | +23.7% |
| Below the 52-week high | it is 20.5% below its highest point of the past year | 20.5% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $31.48 (set on 2014-03-13) | $31.48 |
| Given back of the 52-week move | over the past year its closes ranged ($3.67 to $5.22), and it has given back a bit over half of its rise from last year’s low — 57% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.21 to $4.26. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 57.4% |
| From the all-time high | it is 86.2% below its all-time high | -86.3% |
| Nearest price level | it is trading 1.1% above a support level at $4.28 — a price it turned at five times since 2025-10-24, most recently on 2026-07-23. Since 2024-10-21 it has 11 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.1% |
| All-time low | its lowest closing price on record is $0.8214 (set on 2019-10-21) | $0.8214 |
| Above the all-time low | it is 427.1% above its all-time low | +427.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 88% of the past ~6 months) | 88th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.159 between its high and its low — about 3.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.159 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.92 and $5.00 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.92 – $4.46 – $5.00 |
| Typical daily range (% of price) | its price moves about 3.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.7% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges below its 200-day average price (4.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 31% of its 30-day average | 0.31× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.8% since the prior reading | +0.8% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 9.0% gap up opened on 2026-08-21 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it took 26 sessions to close | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.61% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 14.5 percentage points (the stock lost 13.6% while the market gained 1.0%) | -14.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 5.4 percentage points (the stock lost 1.8% while the market gained 3.6%) | -5.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 14.4 percentage points (the stock lost 5.9% while the market gained 8.5%) | -14.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 19.4 percentage points (the stock lost 4.8% while the market gained 14.6%) | -19.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.3% of the share price. | -10.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.65 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -6.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.85 — a volume-weighted average of daily closes over 49 sessions, not a true tick-by-tick VWAP. | -10.6% |
Double top, bearish — broke down · entry $4.29 · 73 sessions in
Price levels it has turned at before
ABUS last closed at $4.33 on 2026-10-20. Since 2024-10-21 it has turned at 11 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.28 | Support | 1.1% below the last close | turned there five times · 2025-10-24 to 2026-07-23 |
| $4.42 | Resistance | 2.1% above the last close | turned there twice · 2025-12-19 to 2026-08-12 |
| $4.17 | Support | 3.8% below the last close | turned there four times · 2025-09-19 to 2026-04-10 |
| $4.52 | Resistance | 4.4% above the last close | turned there twice · 2026-05-05 to 2026-05-13 |
| $4.06 | Support | 6.2% below the last close | turned there five times · 2025-11-20 to 2026-06-11 |
| $4.64 | Resistance | 7.1% above the last close | turned there four times · 2025-10-01 to 2026-03-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · lagging the market · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$5.40 range $5.40 – $5.40
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Dependence on the success and regulatory approval of clinical-stage product candidates for hepatitis B.","Uncertainty regarding the outcomes and financial recoveries from patent infringement litigation against third parties.","Reliance on third-party collaborations and licensing agreements for future revenue and development progress."]
What changed in the latest 10-Q
AI-assisted comparison of ABUS's 10-Q filed 2026-08-12 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-12) references unaudited condensed consolidated financial statements for the three and six months ended June 30, 2026; older filing (2026-05-13) referenced only the three months ended March 31, 2026.
- Newer filing (2026-08-12) changes the forward-looking bullet regarding Pfizer/BioNTech from 'our patent infringement lawsuit' (singular) to 'our patent infringement lawsuits' (plural).
- Newer filing (2026-08-12) expands the clinical development plans bullet to include 'interactions with regulatory authorities, the incorporation of regulatory feedback into our development programs'.
- Newer filing (2026-08-12) adds a bullet: 'our expectations regarding the receipt, timing and amount of any dividend from Genevant;' not present in older filing (2026-05-13).
- Newer filing (2026-08-12) ends with a page break and the beginning of a section reference; older filing appears truncated at 'and "Part I,' so the newer filing provides slightly more text before cutoff, but no substantive addition is identifiable beyond the cutoff.
- Removed:
- Older filing (2026-05-13) referenced unaudited condensed consolidated financial statements for the three months ended March 31, 2026; newer filing (2026-08-12) references the three and six months ended June 30, 2026.
- Reworded:
- Newer filing (2026-08-12) changes 'our patent infringement lawsuit against Pfizer/BioNTech' to 'our patent infringement lawsuits against Pfizer/BioNTech'.
- Newer filing (2026-08-12) changes the clinical development bullet by adding 'including interactions with regulatory authorities, the incorporation of regulatory feedback into our development programs and clinical collaborations with third parties'; older filing (2026-05-13) stated 'including clinical collaborations with third parties'.
- Notes:
- Both texts are truncated at the end; the comparison covers only the text provided, not the full MD&A sections.
- No materiality or legal conclusions are drawn; only factual text differences are reported.
Risk Factors
- Added:
- Newer filing (2026-08-12) adds: 'In July 2026, we, along with our exclusive licensee Genevant Sciences GmbH, filed three international lawsuits seeking to enforce patents protecting our LNP technology against Pfizer/BioNTech.'
- Newer filing (2026-08-12) adds: 'Moderna made an aggregate $950.0 million noncontingent lump sum payment (the Noncontingent Settlement Payment) to us and Genevant on July 8, 2026. We received $178.4 million on July 8, 2026 as our share of the Noncontingent Settlement Payment, which included reimbursement of our litigation costs.'
- Newer filing (2026-08-12) adds: 'the Company anticipates the payment of a material dividend from Genevant in the third quarter of calendar year 2026.'
- Newer filing (2026-08-12) adds a new sentence: 'In May 2026, we reached alignment with the FDA on the design and safety parameters of a proposed Phase 2b clinical trial evaluating imdusiran for the treatment of cHBV. We intend to incorporate the FDA's feedback into a final Phase 2b protocol.'
- Removed:
- Older filing (2026-05-13) contained: 'Under our license with Genevant, we are entitled to receive, after deduction of litigation costs, 20% of the Noncontingent Settlement Payment. We currently expect to receive an estimated $178.7 million of the Noncontingent Settlement Payment, which includes reimbursement of our litigation costs.' This sentence was removed in the newer filing.
- Older filing (2026-05-13) contained: 'Our current ongoing evaluation of our HBV strategy also includes analysis of imdusiran's potential to suppress HBV DNA replication and HBV RNA and HBsAg expression, without any immunotherapeutics. We are also continuing to evaluate and refine potential Phase 2b clinical trial designs for imdusiran.' This text was removed in the newer filing.
- Older filing (2026-05-13) contained: 'Our HBV product pipeline includes the following: • Imdusiran (AB-729) is our proprietary, GalNAc-conjugated, subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg, which...' This section is not present in the newer filing excerpt.
- Reworded:
- Older filing (2026-05-13): 'our ongoing lawsuit against Pfizer Inc. and BioNTech SE (collectively, Pfizer/BioNTech)'. Newer filing (2026-08-12): 'our ongoing lawsuits against Pfizer Inc., BioNTech SE, and certain of their affiliates (collectively, Pfizer/BioNTech)'.
- Older filing (2026-05-13): 'and any other products that would infringe the asserted patents' not present in older; Newer filing (2026-08-12) adds 'and any other products that would infringe the asserted patents' after 'COVID-19 mRNA-LNP vaccines' in the Pfizer/BioNTech lawsuit description.
- Older filing (2026-05-13): 'Moderna will make an aggregate $950.0 million noncontingent lump sum payment...on or before July 8, 2026'. Newer filing (2026-08-12): 'Moderna made an aggregate $950.0 million noncontingent lump sum payment...on July 8, 2026'.
- Older filing (2026-05-13): 'as of March 31, 2026, we owned approximately 16% of the outstanding common equity of Genevant. We are currently evaluating a return of capital to our shareholders in the third quarter of calendar year 2026, following the receipt of our portion of the Noncontingent Settlement Payment.' Newer filing (2026-08-12): 'The Company owned approximately 16% of the outstanding common equity of Genevant as of June 30, 2026...We are currently evaluating a return of capital to our shareholders in the third quarter of calendar year 2026.'
- Older filing (2026-05-13): 'In February 2022 and April 2023, we filed patent infringement lawsuits in the United States against Moderna and Pfizer/BioNTech, respectively, seeking compensation...' Newer filing (2026-08-12): 'In February 2022 and April 2023, we filed patent infringement lawsuits in the United States against Moderna and Pfizer/BioNTech, respectively, and in March 2025 and July 2026, we filed international patent infringement lawsuits against Moderna and Pfizer/BioNTech, respectively, seeking compensation...'
- Older filing (2026-05-13): 'including ribonucleic acid (RNA) molecules like the messenger RNA (mRNA) utilized in COVID-19 mRNA-LNP vaccines' with parenthetical for mRNA. Newer filing (2026-08-12): 'including ribonucleic acid (RNA) molecules like the mRNA utilized in COVID-19 mRNA-LNP vaccines' removing the 'messenger RNA (mRNA)' parenthetical.
- Older filing (2026-05-13): 'hepatitis B virus RNA (HBV RNA) transcription'. Newer filing (2026-08-12): 'hepatitis B virus RNA (HBV RNA)' without 'transcription'.
- Older filing (2026-05-13): 'reduce associated healthcare costs' at end of long-term outcomes sentence. Newer filing (2026-08-12): truncates to 'further improve long-' without completing the sentence in the excerpt.
- Older filing (2026-05-13): 'our ongoing lawsuit against Pfizer/BioNTech for their use of our patented LNP technology in their COVID-19 mRNA-LNP vaccines' in LNP technology section. Newer filing (2026-08-12): 'our ongoing lawsuits against Pfizer/BioNTech for their use of our patented LNP technology in their COVID-19 mRNA-LNP vaccines and any other products that would infringe the asserted patents'.
- Notes:
- The newer filing excerpt is truncated at 'further improve long-' in the cHBV programs section, preventing full comparison of that section.
- The older filing excerpt is truncated at 'including HBsAg, which' in the product pipeline section, preventing full comparison of that section.
- Some differences may be attributable to excerpt truncation rather than actual filing changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ABUS — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ABUS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 22,711,830
- Reported value $109,016,784
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ABUS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ABUS had 34,053,358 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
ABUS had 17.2% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.53 days to cover at the same settlement.
- Reported short interest (shares) 34,053,358
- Short interest (% of shares outstanding) 17.2%
- Prior settlement (shares) 18,484,910
- Reported change 84.22%
- Days to cover (reported) 3.53
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Pfizer (PFE)
- BioNTech (BNTX)
- Moderna (MRNA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ABUS vs…
ARBUTUS BIOPHARMA CORP is found in…
ABUS shows up in…
Frequently asked questions
What does ARBUTUS BIOPHARMA CORP (ABUS) do?
Arbutus Biopharma Corporation is a biopharmaceutical company focused on the development of therapies for chronic hepatitis B virus (HBV) infection. The company also manages a portfolio of intellectual property related to lipid nanoparticle (LNP) delivery technology, which is the subject of ongoing patent infringement litigation and licensing agreements.
What sector is ARBUTUS BIOPHARMA CORP (ABUS) in?
ARBUTUS BIOPHARMA CORP (ABUS) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ARBUTUS BIOPHARMA CORP's (ABUS) competitors?
Notable peers of ARBUTUS BIOPHARMA CORP (ABUS) include Pfizer, BioNTech and Moderna. This peer set is informational only — not financial advice.
Is ARBUTUS BIOPHARMA CORP (ABUS) overbought or oversold right now?
ARBUTUS BIOPHARMA CORP (ABUS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ABUS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.